 PALO ALTO, Calif. , June 29, 2021 PRNewswire -- Eiger BioPharmaceuticals, Inc. Nasdaq:EIGR, a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced it has received the 2021 Rare Impact Award for Industry Innovation from the National Organization for Rare Disorders NORD for the development and approval of Zokinvy lonafarnib. 